Stricture Definition and Treatment (STRIDENT) Drug Therapy Study
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Crohn Disease
- Inflammatory Bowel Diseases
- Stricture; Bowel
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomised controlled trialMasking: None (Open Label)Masking Description: Open label studyPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Prospective randomised controlled study. Patients with Crohn's Disease who have symptomatic inflammatory intestinal strictures will be randomised to receive standard drug therapy (Anti-TNF monotherapy at standard dose) or intensive drug therapy (Intense Anti-TNF dose induction and escalation for con...
Prospective randomised controlled study. Patients with Crohn's Disease who have symptomatic inflammatory intestinal strictures will be randomised to receive standard drug therapy (Anti-TNF monotherapy at standard dose) or intensive drug therapy (Intense Anti-TNF dose induction and escalation for continued inflammation in combination with thiopurine) for 12 months.
Tracking Information
- NCT #
- NCT03220841
- Collaborators
- Australasian Gastro Intestinal Research Foundation
- AbbVie
- Investigators
- Principal Investigator: Emily Wright, MBBS PhD St Vincent's Hospital Melbourne Principal Investigator: Bronte Holt, MBBS PhD St Vincent's Hospital Melbourne Principal Investigator: Michael Kamm, MBBS PhD St Vincent's Hospital Melbourne